Nutra AI to be used in drug ID study Last week Nurosene Health Inc. ( $MEND.C $MNNDF) announced that it was selected by Mitacs Inc, alongside The University of Toronto to help conduct research into mitochondrial genetics in neuropsychiatric and neurodegenerative diseases.
In this research $MEND's proprietary AI tech, NutraAI will be used to fast-track the identification of novel and commercially viable drug candidates for neuropsychiatric and neurodegenerative diseases.
$MEND was chosen because of positive results from earlier research completed at the UoT using its NetraAI artificial intelligence technology.
Right now $MEND is trading stable at @ $0.68, MC is $22.965M
https://ca.finance.yahoo.com/news/nurosene-announces-research-partnership-designed-130000105.html